BioAtla (BCAB) Payables (2020 - 2026)

BioAtla (BCAB) has reported Payables for 7 consecutive years, with $19.5 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Payables rose 23.15% year-over-year to $19.5 million; the trailing twelve-month figure through Jun 2026 stood at $19.5 million (up 23.15% YoY), and the FY2025 full-year result was $16.4 million, up 19.33% from the prior year.
• Payables grew to $19.5 million in Q2 2026 per BCAB's latest filing, from $19.1 million in the prior quarter.
• Across five years, Payables topped out at $34.0 million in Q3 2023 and bottomed at $13.7 million in Q4 2024.
• Historically, Payables has averaged $20.5 million across 5 years, with a median of $18.7 million in 2024.
• The sharpest annual moves came in 2023 and 2024: Payables surged 56.86% in 2023, then slumped 50.75% in 2024.
• Over 5 years, Payables stood at $21.6 million in 2022, then advanced by 23.65% to $26.7 million in 2023, then plunged by 48.71% to $13.7 million in 2024, then grew by 19.33% to $16.4 million in 2025, then gained by 18.94% to $19.5 million in 2026.
• According to Business Quant data, Payables over the past three periods registered $19.5 million, $19.1 million, and $16.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.